PT3313850T - Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm - Google Patents

Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm

Info

Publication number
PT3313850T
PT3313850T PT16731158T PT16731158T PT3313850T PT 3313850 T PT3313850 T PT 3313850T PT 16731158 T PT16731158 T PT 16731158T PT 16731158 T PT16731158 T PT 16731158T PT 3313850 T PT3313850 T PT 3313850T
Authority
PT
Portugal
Prior art keywords
preparation
amino acid
pharmaceutical compositions
compositions containing
acid derivatives
Prior art date
Application number
PT16731158T
Other languages
English (en)
Portuguese (pt)
Inventor
Perron-Sierra Françoise
Geneste Olivier
Edward Paul Davidson James
Brooke Murray James
Szlávik Zoltán
Csékei MÁRTON
Szabó Zoltán
Sipos Szabolcs
Radics GÁBOR
Bruno Alain
Chen I-Jen
Paczal Attila
Kotschy ANDRÁS
Ondi Levente
Proszenyák AGNES
Bálint BALÁZS
Original Assignee
Vernalis R&D Ltd
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd, Servier Lab filed Critical Vernalis R&D Ltd
Publication of PT3313850T publication Critical patent/PT3313850T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT16731158T 2015-06-23 2016-06-22 Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm PT3313850T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555747A FR3037956B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PT3313850T true PT3313850T (pt) 2018-11-29

Family

ID=54260901

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16731158T PT3313850T (pt) 2015-06-23 2016-06-22 Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm

Country Status (42)

Country Link
US (1) US10457687B2 (https=)
EP (1) EP3313850B1 (https=)
JP (1) JP6741698B2 (https=)
KR (1) KR102620905B1 (https=)
CN (1) CN107709334B (https=)
AR (1) AR105101A1 (https=)
AU (1) AU2016282837B2 (https=)
CA (1) CA2990089C (https=)
CL (1) CL2017003163A1 (https=)
CO (1) CO2017012830A2 (https=)
CR (2) CR20170571A (https=)
CU (1) CU20170164A7 (https=)
CY (1) CY1120991T1 (https=)
DK (1) DK3313850T3 (https=)
EA (1) EA034587B1 (https=)
EC (1) ECSP17082546A (https=)
ES (1) ES2703997T3 (https=)
FR (1) FR3037956B1 (https=)
GE (2) GEAP201914679A (https=)
HK (2) HK1252113B (https=)
HR (1) HRP20181806T1 (https=)
IL (1) IL256191B (https=)
JO (1) JO3430B1 (https=)
LT (1) LT3313850T (https=)
MA (1) MA42232B1 (https=)
MD (1) MD3313850T2 (https=)
MX (1) MX368845B (https=)
MY (1) MY189472A (https=)
PE (1) PE20190111A1 (https=)
PH (1) PH12017502266B1 (https=)
PL (1) PL3313850T3 (https=)
PT (1) PT3313850T (https=)
RS (1) RS57961B1 (https=)
RU (1) RU2747673C2 (https=)
SA (1) SA517390583B1 (https=)
SI (1) SI3313850T1 (https=)
SV (1) SV2017005588A (https=)
TN (1) TN2017000521A1 (https=)
TW (1) TWI631124B (https=)
UA (1) UA123267C2 (https=)
UY (1) UY36733A (https=)
WO (1) WO2016207226A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CN110381937A (zh) * 2017-01-06 2019-10-25 法国施维雅药厂 Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物
TWI753178B (zh) 2017-06-22 2022-01-21 法商施維雅藥廠 Mcl-1抑制劑與血液癌症標準療法之組合,其用途及醫藥組合物
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AR119156A1 (es) 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗cd7抗體藥物結合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
KR101667822B1 (ko) * 2008-04-30 2016-10-19 내셔날 헬스 리서치 인스티튜트 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
JP5694560B2 (ja) * 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ, エセ.アー. Trpa1アンタゴニストとしての2−アミノ−4−アリールチアゾール化合物
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20150307532A1 (en) * 2012-11-20 2015-10-29 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
GEP20207075B (en) 2020-03-10
CL2017003163A1 (es) 2018-06-15
CA2990089A1 (en) 2016-12-29
KR20180015261A (ko) 2018-02-12
FR3037956B1 (fr) 2017-08-04
TN2017000521A1 (en) 2019-04-12
RU2747673C2 (ru) 2021-05-12
CU20170164A7 (es) 2018-05-08
AU2016282837B2 (en) 2020-05-28
ES2703997T3 (es) 2019-03-13
WO2016207226A1 (en) 2016-12-29
MX368845B (es) 2019-10-18
CY1120991T1 (el) 2019-12-11
FR3037956A1 (https=) 2016-12-30
TWI631124B (zh) 2018-08-01
PE20190111A1 (es) 2019-01-15
US20190031675A1 (en) 2019-01-31
JP2018522856A (ja) 2018-08-16
MA42232A (fr) 2016-12-29
RS57961B1 (sr) 2019-01-31
CA2990089C (en) 2020-11-03
EA201890123A1 (ru) 2018-05-31
ECSP17082546A (es) 2018-02-28
KR102620905B1 (ko) 2024-01-04
DK3313850T3 (en) 2019-01-28
PH12017502266B1 (en) 2021-01-13
BR112017027645A2 (pt) 2018-08-28
SI3313850T1 (sl) 2019-01-31
HK1252113B (en) 2020-01-10
SV2017005588A (es) 2018-06-01
HK1250234A1 (zh) 2018-12-07
JO3430B1 (ar) 2019-10-20
HK1252113A1 (en) 2019-05-17
PL3313850T3 (pl) 2019-04-30
GEAP201914679A (en) 2019-11-11
CN107709334A (zh) 2018-02-16
MX2017016996A (es) 2018-08-23
UA123267C2 (uk) 2021-03-10
AR105101A1 (es) 2017-09-06
RU2018102372A3 (https=) 2019-11-06
US10457687B2 (en) 2019-10-29
MD3313850T2 (ro) 2019-02-28
CR20170571A (es) 2018-02-20
LT3313850T (lt) 2018-11-26
IL256191B (en) 2020-03-31
EA034587B1 (ru) 2020-02-25
MA42232B1 (fr) 2018-11-30
NZ738459A (en) 2024-05-31
PH12017502266A1 (en) 2018-06-11
JP6741698B2 (ja) 2020-08-19
UY36733A (es) 2016-12-30
EP3313850A1 (en) 2018-05-02
IL256191A (en) 2018-02-28
CR20170590A (es) 2018-02-26
MY189472A (en) 2022-02-16
CN107709334B (zh) 2021-04-13
CO2017012830A2 (es) 2018-03-28
AU2016282837A1 (en) 2018-01-18
RU2018102372A (ru) 2019-07-23
SA517390583B1 (ar) 2022-02-20
TW201712018A (zh) 2017-04-01
EP3313850B1 (en) 2018-10-03
HRP20181806T1 (hr) 2018-12-28

Similar Documents

Publication Publication Date Title
PT3313850T (pt) Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm
HUE061758T2 (hu) Új hidroxisav-származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerkészítmények
ZA201804770B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA201808286B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
HUE051877T2 (hu) Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
HUE049507T2 (hu) Új piperidinil származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
PT3024826T (pt) Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm
BR112016026205A2 (pt) Moduladores de entrançamento de gene smn2, seu uso e seu processo de preparação, e composições farmacêuticas
PT3357491T (pt) Composição farmacêutica para distribuir um fármaco aniónico
BR112016027595A2 (pt) Produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
EP3284738A4 (en) 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
PT3024833T (pt) Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm
BR112015023453A2 (pt) composição de acil aminoácidos, método para sua produção, célula manipulada e método de preparação de um produto
BR112017017089A2 (pt) complexos de acetato de abiraterona, processo para preparação destes e composições farmacêuticas contendo-os
PT3093018T (pt) Preparação farmacêutica incluindo um composto de ácido piridilaminoacético
DK3348260T3 (da) Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse
BR112017025427A2 (pt) composição farmacêutica oral
PT3620176T (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
PT3689379T (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico
EP3383371A4 (en) PHARMACEUTICAL FORMULATION